Evidence map›Paper›PMID 32476962›Full record

ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2019

Methotrexate treatment efficacy in sarcoidosis might be related to TNF-α polymorphism: real life preliminary study.

Anna Goljan Geremek, Elzbieta Puscinska, Monika Czystowska, Agnieszka Skoczylas, Michal Bednarek, Adam Nowinski, Dorota Gorecka, Urszula Demkow, Pawel Sliwinski

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 73% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Anna Goljan Geremek2nd Department of Respiratory Medicine, National Tuberculosis and Lung Diseases Research Institute, Warsaw Poland.
Elzbieta Puscinska2nd Department of Respiratory Medicine, National Tuberculosis and Lung Diseases Research Institute, Warsaw Poland.
Monika Czystowska2nd Department of Respiratory Medicine, National Tuberculosis and Lung Diseases Research Institute, Warsaw Poland.
Agnieszka SkoczylasGeriatrics Clinic, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Michal Bednarek2nd Department of Respiratory Medicine, National Tuberculosis and Lung Diseases Research Institute, Warsaw Poland.
Adam Nowinski2nd Department of Respiratory Medicine, National Tuberculosis and Lung Diseases Research Institute, Warsaw Poland.
Dorota Gorecka2nd Department of Respiratory Medicine, National Tuberculosis and Lung Diseases Research Institute, Warsaw Poland.
Urszula DemkowLaboratory Diagnostics and Clinical Immunology, Medical University of Warsaw, Poland.
Pawel Sliwinski2nd Department of Respiratory Medicine, National Tuberculosis and Lung Diseases Research Institute, Warsaw Poland.
Masih Daneshvari Hospital · IRMedical University of Warsaw · PLNational Institute of Geriatrics, Rheumatology and Rehabilitation · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMethotrexate therapy improves lung function in selected sarcoidosis patients. Variation in TNF gene was associated with response to treatment. MATERIAL AND

methodsTwenty-eight sarcoidosis patients treated with MTX (6-24 months) were genotyped for

resultsNo correlation between the initial clinical presentation of sarcoidosis and

conclusionTwo types of positive response to MTX therapy (early and late) in chronic respiratory sarcoidosis are associated with polymorphic changes in TNF gene.

Indexed as

Pharmacogenomic VariantsPolymorphism, GeneticAdultFemaleHeterozygoteHomozygoteHumansImmunosuppressive AgentsLungMaleMethotrexateMiddle AgedRecovery of FunctionSarcoidosis, PulmonaryTime FactorsTreatment OutcomeImmunosuppressive AgentsMethotrexateTNF protein, humanTumor Necrosis Factor-alphaMTXsarcoidosisTNF-α polymorphismtreatment

Identifiers

PMID32476962
PMCPMC7247097
OpenAlexW3029459541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.